CD1530 to prevent mouth (oral cavity) squamous cell cancer
CD 1530, an RAR Gamma Agonist for Oral Cavity Squamous Cell Carcinoma Prevention
See if a drug called CD1530 that targets the RARγ receptor can lower the chance of mouth and related esophageal squamous cell cancers in people at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11161389 on NIH RePORTER |
What this research studies
This work focuses on a drug called CD1530 that activates a molecule (RARγ) involved in the lining of the mouth and esophagus. Researchers will build on mouse results that showed fewer cancers with CD1530 and will study how the drug changes gene activity and precancerous changes in oral tissue. The project uses lab models, tissue analyses, and molecular studies to understand how CD1530 might prevent new cancers or recurrences. If findings support safety and clear preventive effects, the team would aim to move toward trials that could involve people at high risk.
Who could benefit from this research
Good fit: People with precancerous mouth lesions or a prior history of oral or esophageal squamous cell carcinoma who are at high risk for recurrence would be the most likely candidates.
Not a fit: People without squamous cell changes in the mouth or those with unrelated conditions or advanced metastatic disease are unlikely to benefit from this prevention-focused work.
Why it matters
Potential benefit: If successful, this could lead to a drug that reduces the risk of new or recurrent oral and esophageal squamous cell cancers.
How similar studies have performed: Retinoid drugs have shown mixed prevention results in humans, and CD1530 reduced tumors in mouse models, but using this selective RARγ agonist for human prevention is novel.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Gudas, Lorraine J — Weill Medical Coll of Cornell Univ
- Study coordinator: Gudas, Lorraine J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.